Company intelligence / Profile preview

Pharmstandard

Ownership: Private
Development stage: Commercial

Overview

Pharmstandard leads the Russian pharmaceutical market with over two decades of experience. It produces more than 400 pharmaceutical products across multiple therapeutic areas. The company operates four GMP-certified manufacturing sites with an annual capacity exceeding 1.7 billion packages. Over 100 of its products are on Russia’s List of Vital and Essential Pharmaceuticals.

Therapeutic areas: OncologyEndocrinologyOtherGastroenterologyCardiovascular
Modalities: Small moleculesBiologics/biotechnology products
Industry: Pharma

Drug pipeline

3 assets

umifenovir

2 more assets in the full pipeline.

Request access →

Partnerships

Joint venture with Generium to develop innovative biological products within Russia’s import substitution program.

Beyond the preview

Go deeper on Pharmstandard.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharmstandard.

Explore the full profile